The project is financed by the Spanish Ministry of Economy and Competition (Ministerio de Economía y Competitividad), and co-financed by the European Regional Development Fund (ERDF; known as FEDER in Spain). It corresponds to the 2016 Challenge-Collaboration (Retos-Colaboración) call of the Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad, aimed at promoting technological development, innovation, and high quality investigation.
It represents funding of 1.45 M euros over 3 years, distributed between Peptomyc (850K euros loan) and the Vall d’Hebron Institute of Oncology (600K euros grant), which are joining forces for this project.
The project title is “Pre-clinical Development of Omomyc-CPP as a therapy for cancer treatment” (“Desarrollo pre-clínico de Omomyc-CPP como terapia para el tratamiento del cáncer”), with code RTC-2016-5079-1.
This is a very significant round of funding and further shows the strong support for this project both within Spain and the European Commission. It will help to advance development of the Omomyc peptide towards its clinical use for cancer treatment.